An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

Trial Profile

An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2018

At a glance

  • Drugs Minocycline (Primary)
  • Indications Rosacea
  • Focus Registrational; Therapeutic Use
  • Sponsors Foamix
  • Most Recent Events

    • 27 Jun 2018 according to the Foamix media release, top-line results are expected in the first half of 2019.
    • 27 Jun 2018 Status changed from recruiting to active, no longer recruiting, according to the Foamix media release.
    • 28 Feb 2018 According to a Foamix media release, the expected timing of an NDA filing for FMX103 is planned for 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top